A novel polyrotaxane-based delivery system for scutellarin: preparation, characterization, and in vitro evaluation  by Jiang, Rui-Jian et al.
Carbohydrate Research 380 (2013) 149–155Contents lists available at ScienceDirect
Carbohydrate Research
journal homepage: www.elsevier .com/locate /carresA novel polyrotaxane-based delivery system for scutellarin:
preparation, characterization, and in vitro evaluation0008-6215 2013 The Authors. Published by Elsevier Ltd.
http://dx.doi.org/10.1016/j.carres.2013.07.009
⇑ Corresponding author. Fax: +86 0871 65920637.
E-mail addresses: yangbo6910@sina.com, 576424704@qq.com (B. Yang).
O
HO
HO
OH
HOOC
O O
HO
OH O
OH
A B
C
Scheme 1. The structure of scutellarin.
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CytotoxicityThe safe and effective polyrotaxane-based drug delivery system could potentially increase the antiprolif-
erative activity of antitumor medicine. A novel scutellarin–polyrotaxane (SCU–PR), in which scutellarin
(SCU) was covalently bound to one of the hydroxyl groups of polyrotaxane (PR), was synthesized, and
its characterization was further investigated by NMR, XRD, TG, DSC. The cytotoxicity of SCU–PR was
assessed in vitro using human HCT116 and LOVO cell lines in results that the IC50 values of SCU–PR
(1.03  106 and 1.01  106 mol/L, respectively), which compared with those of free SCU (7.80  105
and 7.70  105 mol/L, respectively), were lower. The valuable properties of SCU–PR will be potentially
useful for its application on human colon cancer chemotherapies.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction fect on cerebral I/R injury.3 In recent years, it has been reportedScutellarin (40,5,6-trihydroxyﬂavone-7-glucuronide, SCU)
(Scheme 1), is an active ingredient extracted from traditional Chi-
nese medicine Erigeron breviscapus (vant) Hand-Mazz., which has
been clinically used to treat acute cerebral infarction and paralysis
induced by cerebrovascular diseases in China since 1984.1,2 The
protective activity of scutellarin against cerebral Ischemia/Reper-
fusion (I/R) injury in rat MCAO model has been established, the
mechanism is the scavenging effect on reactive oxygen species
(ROS). Scutellarin could clean ROS and subsequently prevent the
loss of glutamine synthetase (GS) activity, displaying protective ef-that scutellarin can induce cell death in the human colon cancer
cell line.4 Scutellarin can also inhibit tumor proliferation and
migration, and regulate cell adhesion in oral squamous cell carci-
noma (OSCC).5 However, the exact mechanisms remain uncon-
ﬁrmed. The blocking of cell cycle maybe one of the mechanisms
of SCU’s activity by which the growth and proliferation of tumor
cells are inhibited.6 Nevertheless, some obvious shortcomings
including the low bioavailability and the low stability become
obstacles of SCU to use for clinical purposes. For above reasons, a
safe and effective delivery system is needed urgently.
Cyclodextrin-based polyrotaxane has attracted more and more
attention due to their wide applications in pharmaceutics area.6–
11 Polyrotaxanes could target the drug to its activity sites, increase
the stability of drug, and enhance the aqueous solubility of the
hydrophobic drug.12 Due to their excellent biocompatibility, cyclo-
dextrins including a-cyclodextrin (a-CD), b-cyclodextrin (b-CD),
and c-cyclodextrin (c-CD) have been widely used as macrocycle
units to construct polyrotaxane delivery carriers. Generally, poly-
mers (e.g., polypropylene glycol, PPG) and cyclodextrins are assem-
bled in an aqueous solution due to the hydrophobic interaction
between inner core-forming portions of cyclodextrins.13 The abun-
dance in functional hydroxyl groups on the CD residues renders
polyrotaxanes capability of carrying a large dose of hydrophobic
drugs.12,14,15 For instance, Moon prepared camptothecin–polyro-
taxane and doxorubicin–polyrotaxane using polyethylene glycol
(PEG) as polymer, which possessed satisfactory cytotoxicity and
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Scheme 2. Chemical structure of SCU-NH-b-CD conjugate (SCU-Conjugate).
150 R.-J. Jiang et al. / Carbohydrate Research 380 (2013) 149–155caused less side effects because of enhancing selectivity.15,16 Some
macromolecules which form nanostructure carriers can selectively
collect and accumulate in the interstitial space of the tumor cells
due to the existence of the enhanced permeability and retention
effect (EPR effect).16
In our previous work, we synthesized the SCU-NH2-b-CD conju-
gate (SCU-Conjugate, Scheme 2), in which SCU was covalently
bound to one of the primary hydroxyl groups of b-CD. In vitro
assessment studies indicated the cytotoxicity of SCU-Conjugate
on human colon cancer cell lines LOVO and HCT116 was better
than that of SCU alone.17 In this paper, we prepared a novel scutell-
arin–polyrotaxane (SCU–PR), in which scutellarin (SCU) was
covalently bound to one of the hydroxyl groups of polyrotaxane
(PR), was synthesized, and its characterization was further investi-
gated by NMR, XRD, TG, and DSC. The cytotoxicity of SCU–PR was
assessed in vitro using human HCT116 and LOVO cell lines to
demonstrate the potential of PR-based SCU delivery system. The
valuable properties of SCU–PR will be potentially useful for its
application on human colon cancer chemotherapies.
2. Results and discussion
2.1. Synthesis
SCU–PR was prepared in four steps (Scheme 3). Polyrotaxane 4
was synthesized by threading mono (6-azido-6-deoxy)-b-CD
(N3-b-CDs) residues onto a PPG–NH2 chain, blocking the two ends
of the PPG–NH2 with bulky mono (6-O-succinic-6-deoxy)-b-CD.
Polyrotaxane 4 was reduced by treatments with triphenylphos-
phine (PPh3) in DMF and then with ammonium hydroxide. The
polyrotaxane 5 was coupled to the SCU carboxyl group which
was ﬁrst activated using Dicyclohexylcarbodiimide (DCC) in the
presence of a small amount of 4 Å molecular sieves. The puriﬁed
scutellarin–polyrotaxane (SCU–PR) 6 was obtained by dialyzing
in Spectra/PorCE (MWCO = 3500).
2.2. NMR, XRD, TG, and DSC characterization
2.2.1. NMR characterization and aqueous solubility
As described in Scheme 3, the PR–SCU conjugate was synthe-
sized by threading the b-CD residues onto a PPG chain, end-cap-
ping the two ends of the PPG chain with bulky CD groups. Theaverage number of b-CD of polyrotaxane or pseudo-polyrotaxane
can be calculated to compare the integrations of the signals at
4.95 ppm (C1-H of b-CD) with those at 1.04 ppm (CH3 of PPG).
According to the NMR spectrum and the molecular weight of the
PPG (approximate 2000), the pseudo-polyrotaxane 2 and polyro-
taxane 4 were calculated to possess 11 and 13 b-CD, respectively.
This result indicates that the end-capping reactions had actually
end-capped the pseudo-polyrotaxane 2. Figure 1 shows the NMR
spectrum of the synthesized PR–SCU conjugate, with peaks of the
signals at 4.95 ppm (C1-H of b-CD), 7.7–7.9 ppm (20,60-H of SCU),
and 6.7–6.9 ppm (30,50-H of SCU). As demonstrated by the related
peaks for SCU, CD, and PPG, it was clear that the desired SCU–PR
conjugate was successfully synthesized. The overall yield of the
SCU–PR was 54%, whereas the average weight content of SCU in
the conjugate was approximately 18.0% (w/w) (Table 1). The
molecular weight of the SCU–PR conjugate, as determined by the
1H NMR data, was approximately 20 kDa. Based on these results,
each SCU–PR was calculated to possess one PPG chain, 11 b-CD res-
idues, and 8 SCU drug molecules.
The aqueous solubility of polyrotaxane 5 is assessed by the
preparation of its saturated solution. The results show that the
water solubility of polyrotaxane 5 was 42 mg/mL at room temper-
ature. When 8 molecules of SCU are bonded covalently to the
polyrotaxane 5, the aqueous solubility of SCU–PR conjugate re-
duces to 34 mg/mL, which is still better than that of SCU alone
and SCU-Conjugate respectively (Table 2).
2.2.2. X-ray diffraction characterization
Powder XRD patterns allow examination of the medium and
long range ordering of materials.18 The powder X-ray diffraction
patterns of SCU, mono (6-amino-6-deoxy)b-CD (NH2-b-CD), SCU-
Conjugate, and SCU–PR are illustrated in Figure 2. We can see that
free SCU (Fig. 2d) is in crystalline form, but the NH2-b-CD (Fig. 2a)
and SCU-NH2-b-CD (Fig. 2b) conjugate are amorphous structure. In
contrast to the amorphous character of SCU-Conjugate, the SCU–PR
(Fig. 2c) is in crystalline form, the reason may be that NH2-b-CD
formed an ordered arrangement on the PPG.
2.2.3. Thermal analysis and differential scanning calorimetry
characterization
The thermal properties of the SCU–PR were investigated by
thermogravimetry (TG). The analysis on TG curves showed that
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Scheme 3. The preparation of SCU–PR.
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SCU-Conjugate decomposes at ca. 310 C (Fig. 3b) and ca. 320 C
(Fig. 3c). However, the SCU showed different thermal stability, that
is, the decomposition temperatures were ca. 220 C and ca. 360 C
(Fig. 3a). These phenomena in which the thermal properties of
SCU–PR were similar to those of SCU-Conjugate indicated that
the order arrangement of polyrotaxane does not change the typical
thermal property of SCU-Conjugate.
The differential scanning calorimetry (DSC) thermogram can
give the further information about the thermal property of SCU–
PR. As shown in Figure 4, the DSC curve of SCU displays threeendothermic peaks at 130, 210, and 370 C. In contrast, the DSC
curve of NH2-b-CD showed endothermic peak at 320 C, SCU-Con-
jugate, SCU–PR showed exothermic peak at 320 C, the results indi-
cated likewise that the thermal property of SCU–PR is similar to
SCU-Conjugate.
2.3. Fluorescence intensity measurements
Rhodamine B (RhB) was used as a probe to detect the released
SCU-Conjugate because inclusion complexation between
chemically modiﬁed b-CD and RhB increases the ﬂuorescent
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Figure 2. Powder X-ray diffractograms (Cu-ja) for: (a) NH2-b-CD, (b) SCU-
Conjugate, (c) SCU–PR, (d) SCU.
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Figure 1. 1H NMR spectra of pseudo-polyrotaxane 2 (a) and SCU–PR (b).
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Figure 4. DSC diagrams of (a) SCU–PR, (b) SCU, (c) NH2-b-CD, (d) SCU-Conjugate.
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Figure 3. TG curves for: (a) SCU, (b) NH2-b-CD, (c) SCU-Conjugate, (d) SCU–PR.
152 R.-J. Jiang et al. / Carbohydrate Research 380 (2013) 149–155intensity. The ﬂuorescent intensity of RhB (6.0  107 mol/L) in a
phosphate buffer at pH 1.5, 4.0, 7.2, and 8.0 were 346, 392, 650,
and 471 a.u., respectively. In presence of mono[6-(2-amino)-6-
deoxy]-b-cyclodextrin (NH2-b-CD, 6.0  105 mol/L), the intensity
was increased, indicating inclusion of RhB into the NH2-b-CD cav-
ity. After adding polyrotaxane 5 (6.0  106 mol/L) to the buffers
with dissolved RhB, the ﬂuorescent intensity of RhB was not chan-
ged. This result also showed no free NH2-b-CD in polyrotaxane 5.
By ﬁve min after the addition, the intensity was slightly increased,
as compared that the intensity was increased obviously at 1 h later,
which reached around 455 a.u. at pH 1.5 (Fig. 5). These results indi-
cate that the hydrophobic cavities of the NH2-b-CDs are exposed in
the buffer due to cleavage of terminal amido bonds, especially in
acidic region, and the release of SCU-Conjugate by hydrolysis from
the SCU–PR was also examined in vitro under physical conditions.
Within ﬁrst 5 h of incubation, a burst release of SCU-Conjugate was
observed, with less than 20% of total terminal bonds hydrolyzed.
After the initial effect, a nearly linear and sustained release proﬁle
of the SCU-Conjugate was seen over an extended period. By day 3,
more than 75% of SCU-Conjugate on SCU–PR had been released by
hydrolysis (Fig. 6).
2.4. In vitro cytotoxicity studies
The cytotoxicity tests for SCU and SCU–PR were evaluated
in vitro for antiproliferative activity against human HCT116 and
LOVO cell lines by the MTT cytotoxicity assay. The IC50 values
that represented the concentration of a drug required for 50%
reduction of cellular growth had been calculated. The SCU–PR
presented a satisfactory antiproliferative activity against HCT116Table 2
Aqueous solubility of SCU, SCU-Conjugate, polyrotaxane 5, and SCU–PR
SCU SCU-Conjugate Polyrotaxane 5 SCU–PR
Aqueous solubility (mg/mL, 298 K) 0.16 ± 0.01 25 ± 0.5 42 ± 0.5 34 ± 0.5
Table 1
Preparation of SCU–PR
Stoichiometric No. of b-CD No. of b-CD threadinga No. of SCUb M.W. (Da)c % of threadingd % of SCUe Weight content of SCUf
SCU–PR 17 11 8 ca. 20,400 64.7% 72.7% 18%
a–c Calculated from 1H NMR spectra.
d Stoichiometric (calculated) number of b-CD onto a PPG-NH2 (Mn  2000) is ca.17, assuming one b-CD molecule threads two poly (propylene glycol) units which total 34
units. % of threading = [No. of b-CD threading]/[Stoichiometric No. of b-CD].
e % of SCU = [No. of SCU]/[No. of b-CD threading].
f Weight content of SCU = [M.W. of SCU (462)  No. of SCU (8)]/[M.W. of SCU–PR (20,400)].
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R.-J. Jiang et al. / Carbohydrate Research 380 (2013) 149–155 153and LOVO, its IC50 values were 1.03  106 and 1.01  106 mol/L
which were lower than those of free SCU (7.80  105 and
7.70  105 mol/L, respectively) alone and those of SCU-Conjugate
(4.50  105 and 5.20  105 mol/L, respectively) (Fig. 7). On con-
trol tests, the IC50 values of polyrotaxane 5 exceed 5  103 mol/L
in HCT116 and LOVO, indicating that polyrotaxane 5 was very
nontoxic to the two cell lines tested. These results proved that
the increase in cytotoxicity was attributable to the formation of
SCU–PR, in which scutellarins were bound to one of primary hy-
droxyl groups of PR.In addition, the antiproliferative activities of SCU–PR, free SCU
and SCU-Conjugate against human HCT116 and LOVO cell lines
at different concentrations are shown in Figures 8 and 9, respec-
tively. From the two ﬁgures, we can deduce that the concentration
dependence of the antiproliferative activity of SCU–PR in vitro cell
is somewhat different from that of free SCU and SCU-Conjugate.
Free SCU exhibits a very effective antiproliferative activity against
HCT116 and LOVO at a concentration higher than 1  106 mol/L.
However, when further diluting the SCU solution to 1 
108 mol/L or lower, its activity decreases sharply. In contrast,
the antiproliferative activity of SCU–PR displays a much slower de-
cline tendency when its concentration decreases from 1  105 to
1  109 mol/L, which will be potentially useful to its clinical
application.
This ﬁnding was expected, as the antitumor activities of SCU-
Conjugate were better than those of scutellarin with the capability
of b-CD cavity of SCU-Conjugate to include cholesterol or lecithin
of cell membranes in our previous work.17 In contrast the mem-
brane-impermeable, macromolecular SCU–PR could not be inter-
nalized by the cells to induce the cytotoxic effects of SCU.
Interestingly but as anticipated, the IC50 values of SCU–PR were
lower than those of free SCU and SCU-Conjugate, which can be ac-
counted for in terms of the following reasons. As the SCU–PR could
be hydrolyzed to release SCU-Conjugate in vitro under physiologi-
cal conditions (Fig. 5), and each SCU–PR possessed 8 SCU drug
molecules with satisfactory aqueous solubility, these ﬁnding ren-
der SCU–PR to remain antiproliferative activity at a lower dosage
compared with SCU alone and SCU-Conjugate. On the control test,
ﬂuorescent anthracene-9-carboxylic acid polyrotaxane was syn-
thesized (Scheme 4). Confocal ﬂuorescence images showed that
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Scheme 4. Anthracene-9-carboxylic acid polyrotaxane.
Figure 10. Confocal ﬂuorescence image of HCT116 cells incubated with anthra-
cene-9-carboxylic acid polyrotaxane.
154 R.-J. Jiang et al. / Carbohydrate Research 380 (2013) 149–155HCT116 cells treated with anthracene-9-carboxylic acid polyrotax-
ane exhibited red ﬂuorescence (Fig. 10).
3. Conclusion
In conclusion, we successfully prepared the scutellarin–polyro-
taxane (SCU–PR), which possessed one PPG chain, 11 b-CD resi-
dues, and 8 SCU drug molecules, and had much higher aqueous
solubility than scutellarin, and could be hydrolyzed to SCU-
NH2-b-CD conjugate (SCU-Conjugate) in aqueous solution. In vitro
cytotoxicity studies, the SCU–PR had higher antiproliferative activ-
ities than free SCU and SCU-Conjugate. The reasons would be that
the SCU–PR could be hydrolyzed to release SCU-Conjugate in vitro
under physiological conditions, and each SCU–PR possessed 8 SCU
drug molecules with satisfactory aqueous solubility. These valu-
able properties of the SCU–PR will enable its potential application
on new treatment for human colon cancer.
4. Experimental
4.1. Materials
b-Cyclodextrin (b-CD) was commercially available. N, N-
Dimethylformamide (DMF) was dried over calcium hydride for
2 days and distilled under a reduced pressure prior to use. Scutell-
arin was obtained by Kunming Pharmaceutical Corporation (PC
>99%) in Yunnan Province, PR China. Poly (propylene glycol) bis
(2-aminopropyl ether) (PPG–NH2, average Mn 2000) was commer-
cially available (AlDRich Chemistry). Dicyclohexylcarbodiimide
(DCC) was commercially available (Shanghai Reagent Factory)and used without further puriﬁcation. Other chemicals and sol-
vents were of analytical-reagent grade.
4.2. Preparation of mono (6-azido-6-deoxy)b-CD (N3-b-CD) (1)
6-p-Toluenesulfonyl-b-cyclodextrin (6-OTS-b-CD, 6.500 g,
5.00 mmol, prepared by the method of Vitzitiu19), and sodium
azide (NaN3, 0.4000 g, 6.00 mmol) were dissolved in anhydrous
N, N-Dimethylformamide (DMF, 25 mL). The reaction mixture
was stirred for 10 h at 75 C (prepared by the method of Nielsen20).
The overall yield was 84%. 1H NMR (500 MHz, DMSO-d6, ppm): d
5.65–5.85 (m, CD’s C2,3-OH), d 4.95 (s, CD’s C1-H), d 4.45–4.65 (m,
CD’s C6-OH), d 3.30–3.95 (m, CD’s C2,3,4,5,6,7-H).
4.3. Preparation of polypseudorotaxane (2)
A saturated aqueous solution of 1 containing 2.318 g
(2.00 mmol) N3-b-CD was put into 2000 mL round-bottomed ﬂask.
PPG–NH2 (3.744 g, ca. 1.80 mmol) was added at room temperature
with mechanical agitation for 72 h. The precipitate was collected
by centrifugation, washed with water and acetone, and then dried
under vacuum up to 50 C. The overall yield was 77%. 1H NMR
(500 MHz, DMSO-d6, ppm): d 5.65–5.75 (m, CD’s C2,3-OH), d 4.95
(s, CD’s C1-H), d 4.40–4.65 (m, CD’s C6-OH), d 3.35–3.95 (m, CD’s
C2,3,4,5,6,7-H), d 1.02–1.03 (s, CH3 of PPG).
4.4. Preparation of mono (6-O-Succinic-6-deoxy)b-CD (3)
b-Cyclodextrin (b-CD, 1.134 g, 1.00 mmol) was dissolved in
anhydrous N, N-Dimethylformamide (DMF, 10 mL), then added
pyridine 5 mL and succinic anhydride (0.090 g, 0.90 mmol). The
reaction mixture was stirred for 18 h at room temperature (pre-
pared by the method of Cucinotta).21,22 The overall yield was
60%. 1H NMR (500 MHz, DMSO-d6, ppm): 1H NMR (500 MHz,
DMSO-d6, ppm): d 5.75–5.95 (m, CD’s C2,3-OH), d 4.85 (s, CD’s
C1-H), d 4.45–4.65 (m, CD’s C6-OH), d 3.30–3.95 (m, CD’s
C2,3,4,5,6,7-H), d 2.70–2.73 (m, –CH2–CH2– of mono (6-O-Succinic-
6-deoxy)b-CD).
4.5. Preparation of polyrotaxane (4)
Dicyclohexylcarbodiimide (DCC, 0.1768 g, 0.870 mmol), 3
(1.165 g, 0.940 mmol) and a small amount of 4 Å molecular sieves
were dissolved in anhydrous N,N-Dimethylformamide (DMF,
25 mL). The reaction mixture was stirred for 1 h in an ice bath, then
2 (0.8500 g, ca. 0.058 mmol) was added. This reaction was stirred
for 2 days at room temperature. The precipitate was removed by
ﬁltration and the ﬁltrate was poured into 600 mL of acetone to
get white precipitate, and then dried under vacuum up to 50 C.
The overall yield was 68%. 1H NMR (500 MHz, DMSO-d6, ppm): d
5.55–5.85 (m, CD’s C2,3-OH), d 4.90 (s, CD’s C1-H), d 4.45–4.60 (m,
R.-J. Jiang et al. / Carbohydrate Research 380 (2013) 149–155 155CD’s C6-OH), d 3.30–3.95 (m, CD’s C2,3,4,5,6,7-H), d 2.70–2.83 (m, –
CH2–CH2– of mono (6-O-Succinic-6-deoxy)b-CD), d 1.00–1.05 (s,
CH3 of PPG).
4.6. Preparation of polyrotaxane (5)
4
(2.056 g, ca. 0.110 mmol) and triphenylphosphine (PPh3,
0.1441 g, 0.550 mmol) was dissolved in anhydrous N,N-Dimethyl-
formamide (DMF, 10 mL), the mixture was stirred at room temper-
ature for about 3 h. then double-distilled water (10 mL) was added,
the reaction was stirred at room temperature for about 24 h. The
reaction solution was concentrated under reduced pressure, a large
amount of acetone (300 mL) was added, and the resulting precipi-
tate was ﬁltrated, dried under vacuum up to 50 C. The overall
yield was 60%. 1H NMR (500 MHz, DMSO-d6, ppm): d 5.55–5.85
(m, CD’s C2,3-OH), d 4.90 (s, CD’s C1-H), d 4.35–4.55 (m, CD’s
C6-OH), d 3.30–3.95 (m, CD’s C2,3,4,5,6,7-H), d 2.70–2.83 (m, –CH2–
CH2– of mono (6-O-Succinic-6-deoxy)b-CD), d 1.00–1.05 (s, CH3
of PPG).
4.7. Preparation of SCU–PR (6)
Dicyclohexylcarbodiimide (DCC, 0.2454 g, 1.20 mmol) and Scu-
tellarin (SCU, 0.5544 g, 1.20 mmol) were dissolved in anhydrous N,
N-Dimethylformamide (DMF, 10 mL). The reaction mixture was
stirred for 1 h in an ice bath, then 5 (2.056 g, 0.110 mmol) was
added. This reaction was stirred for 2 days at room temperature.
The precipitate was removed by ﬁltration and the ﬁltrate was
poured into 400 mL of acetone. The precipitate was collected by
centrifugation and dried in vacuo to give a crude product. The
crude product was dissolved in double-distilled water. The aque-
ous solution was dialyzed in double-distilled water for 3 days
using Spectra/PorCE (MWCO = 3500). The overall yield was 54%.
1H NMR (500 MHz, DMSO-d6, ppm): d 12.75 (s, 5-OH of SCU), d
10.38 (s, 6-OH of SCU), d 8.65 (s, 40-OH of SCU), d 7.75–7.95 (m,
20,60-H of SCU), d 6.75–6.95 (m, 8H,3-H and 30,50-H of SCU), d
5.55–5.95 (m, CD’s C2,3-OH), d 4.95 (s, CD’s C1-H), d 4.35–4.55 (m,
CD’s C6-OH), d 3.30–3.95 (m, CD’s C2,3,4,5,6,7-H), d 2.54–2.75 (m, –
CH2–CH2– of mono (6-O-Succinic-6-deoxy)b-CD), d 1.04–1.05 (s,
CH3 of PPG).
4.8. Characterization of SCU–PR
1H NMR experiment was measured with a Bruker Avance
DRX500 spectrometer at 298 K in DMSO-d6. Samples were kept
at least 24 h before measurement for equilibration.
Powder X-ray diffraction (XRD) was performed with a D/max-
3B diffractometer using (Cu-ja) (j = 15,460 Å) using 30 mA,
40 kV, and a scanning rate of 5/min. Powder samples were
mounted on a sample holder and scanned with a step size of
2h = 0.02 between 2h = 3 and 70.
Thermal analyses (TG) were recorded on a NETZSCH STA449F3
instrument, with a 10 C/min heating rate from temperature to
500 C under N2 ﬂow (100 mL/min).
4.9. Measurement of aqueous solubility
The aqueous solubility was assessed by the preparation of its
saturated aqueous solution. An excess amount of polyrotaxane
was put into 20 mL of water (pH ca. 7), and the mixture was stirred
for 1 h. After removing the insoluble substance by ﬁltration, the ﬁl-
trate was evaporated under reduced pressure to dryness, and the
residue was dosed by a weighing method.4.10. Fluorescence intensity measurements
Fluorescence intensity measurements were operated using the
method of Ooya.18 The SCU–PR (10 mg) was dissolved in 100 mL
of a phosphate buffer containing Rhodamine B (6.0  107 mol/L).
The excitation wave length was set to 550 nm, and the emission
wave length was set to 574 nm. The pH of the phosphate buffer
solution was adjusted to 1.5, 4.0, 7.2, 8.0 by adding 1 N hydrochlo-
ric acid and 1 N sodium hydroxide.
4.11. In vitro cytotoxicity studies
Cells were cultured at 5  105/mL in RPMI 1640 supplemented
with 10% heat-inactivated fetal bovine serum at 37 C in a humid-
iﬁed atmosphere of 5% CO2 in air. Cells were seeded at 5  104/mL
and treated with the indicated amounts of the complex. The effect
of the polyrotaxane was evaluated as cell survival after treatment.
Cell viability was evaluated by a microculture tetrazolium reduc-
tion assay using MTT (3-(4,5-dimethyltriazol-2-yl) 2,5-diphenyl-
tetrazolium bromide; Sigma). Brieﬂy, 50 mL of MTT stock
solution (2 mg/mL in PBS) was added to 150 mL cell cultures in
96-microwell ﬂat-bottom plates for 4 h incubation at 37 C. Plates
were then centrifuged and MTT-containing culture medium
removed. Precipitated formazan was dissolved in 150 mL DMSO.
Results were read with 15 min in a spectrometer at 490 nm, and
the means of triplicates were calculated. Cell inhibition rate is ex-
pressed as percentage of control samples.
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